Industry
Biotechnology
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Loading...
Open
0.45
Mkt cap
43M
Volume
1.8M
High
0.47
P/E Ratio
-1.35
52-wk high
1.82
Low
0.42
Div yield
N/A
52-wk low
0.20
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.